Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OGN-IL17
- Development stage
- Preclinical
- Lead developer
- OroGen BioSciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OGN-IL17 is a preclinical-stage small molecule inhibitor targeting interleukin-17 (IL-17), currently under development by Orogen Therapeutics. The program is focused on treating inflammatory skin conditions, specifically plaque psoriasis and hidradenitis suppurativa. As a small molecule, it aims to provide an alternative to existing monoclonal antibody therapies targeting the IL-17 pathway, potentially offering different routes of administration or improved tissue penetration. The asset is currently in the IND-enabling (Investigational New Drug) phase of development.
- Other names
- IL-17 programIL17 programIL 17 programIL-17 DC CohortIL17 DC CohortIL 17 DC Cohort
02
Targets
IL-17A (Interleukin-17A)
Beyond the preview
Go deeper on OGN-IL17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OGN-IL17.